Lixte Biotechnology files new patent application for treatment of brain tumors
John Kovach, president and CEO of Lixte, said: “Lixte has developed a series of novel compounds that inhibit the growth of common brain cancers of adults and children
Life science tools and diagnostics provider Bio-Techne Corporation has opened a new manufacturing facility in Bristol, UK, dedicated to good manufacturing practice (GMP) grade small molecules.
Under the co-operative R&D agreement, BN ImmunoTherapeutics has rights to exclusively license intellectual property that results from this collaboration. Bavarian Nordic will in the future explore opportunities for